Sunita Zalani

Consigliere Generale presso Intarcia Therapeutics, Inc.

Health Technology

Consumer Services

Profilo

Sunita Zalani is currently the Vice President-Global Regulatory Affairs & Quality at Intarcia Therapeutics, Inc. Prior to her current position, she worked as the Executive Director-Global Regulatory Affairs at Amgen, Inc. from 2004 to 2012.
She also worked as the Vice President-Global Regulatory Affairs at Onyx Pharmaceuticals, Inc. and as a Global Regulatory Lead at Eli Lilly & Co. Dr. Zalani holds a doctorate degree from the University of Baroda.

Posizioni attive di Sunita Zalani

Società	Posizione	Inizio
Intarcia Therapeutics, Inc. Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.	Consigliere Generale	05/08/2014

Tutte le posizioni attive di Sunita Zalani

Precedenti posizioni note di Sunita Zalani

Società	Posizione	Fine
AMGEN INC.	Consigliere Generale	01/05/2012
ELI LILLY AND COMPANY	Corporate Officer/Principal	-
Onyx Pharmaceuticals, Inc. Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA.	Consigliere Generale	-

Vedi nel dettaglio l'esperienza di Sunita Zalani

Formazione di Sunita Zalani

University of Baroda

Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Sunita Zalani

Relazioni

100 +

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	2
AMGEN INC.	Health Technology
ELI LILLY AND COMPANY	Health Technology

Aziende private	2
Intarcia Therapeutics, Inc. Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.	Health Technology
Onyx Pharmaceuticals, Inc. Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA.	Health Technology